Valuation: Tonix Pharmaceuticals Holding Corp.

Market Cap 17Cr 15Cr 14Cr 13Cr 24Cr 1.62TCr 24Cr 167.71Cr 65Cr 828.04Cr 63Cr 62Cr 2.66TCr P/E 2026 *
-1.01x
P/E 2027 * -1.49x
Enterprise Value 17Cr 15Cr 14Cr 13Cr 24Cr 1.62TCr 24Cr 167.71Cr 65Cr 828.04Cr 63Cr 62Cr 2.66TCr EV / Sales 2026 *
3.07x
EV / Sales 2027 * 1.53x
Free-Float
99.84%
Yield 2026 *
-
Yield 2027 * -
22/09 Tonix Pharmaceuticals Holding Corp. Announces Second Major Managed Medicare Payer Agreement for TONMYA® CI
08/09 Tonix Pharmaceuticals Holding Corp. Announces Appointment of Thomas Englese to Chief Commercial Officer, Effective September 8, 2026 CI
19/08 Tonix Pharmaceuticals Holding Corp. Announces Appointment of Seth Lederman as Interim Chief Medical Officer CI
10/08 Tonix Pharmaceuticals Holding Corp., Q2 2026 Earnings Call, Aug 10, 2026
10/08 Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
03/08 Tonix Pharmaceuticals Announces Positive Minutes From Type C FDA Meeting To Discuss Adaptive Phase 2 Field Study Of TNX-4800, A Human, Anti-OspA Monoclonal Antibody, To Prevent Lyme Disease In The US CI
22/07 Tonix Pharmaceuticals Holding Corp. Announces Retirement of Gregory M. Sullivan as Chief Medical Officer, Effective August 20, 2026 CI
15/07 Tonix Pharmaceuticals Advances Tnx-801 Live Attenuated Minimally Replicative Investigational Vaccine Candidate Based on Horsepox Virus to Protect Against Mpox Disease CI
13/07 Tonix Pharmaceuticals Holding Corp. Announces Major Managed Medicare Agreement for Tonmya and Expands Pharmacy Coverage CI
13/07 Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment MT
29/06 Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study MT
29/06 Tonix Pharmaceuticals Holding Corp Announces First Patient Enrolled in Phase 2 Horizon Study of TNX-102 SL For Major Depressive Disorder CI
25/06 Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT MT
1 day+1.65%
1 week-9.29%
Current month-30.07%
1 month-27.71%
3 months-25.42%
6 months-28.29%
Current year-36.88%
1 week 9.62
Extreme 9.62
11.19
1 month 9.62
Extreme 9.62
14.5
Current year 9.4
Extreme 9.4
19.95
1 year 9.4
Extreme 9.4
25.52
3 years 6.76
Extreme 6.76
2,416
5 years 6.76
Extreme 6.76
4,00,000
10 years 6.76
Extreme 6.76
60,25,64,102.56
Manager TitleAgeSince
Chief Executive Officer 68 16/11/2007
Director of Finance/CFO 52 01/02/2016
Chief Tech/Sci/R&D Officer 57 04/02/2025
Director TitleAgeSince
Chairman 68 01/10/2011
Director/Board Member 66 12/09/2017
Director/Board Member 81 05/09/2018
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/26 Other

Executive/Senior Manager

60,174 0.5110%
27/08/26 Buy

Chief Executive Officer

2,000 0.0170%
20/08/26 Buy

Director

1,000 0.0085%
Change 5-day change 1-year change 3-year change Capi.($)
+1.65%-9.29%-59.27%-99.61% 17Cr
+0.13%+2.65%+63.34%+115.17% 1,05500Cr
+0.20%+0.46%+50.92%+70.56% 65TCr
-0.29%+0.14%+19.82%+71.75% 47TCr
-0.85%+0.98%+42.13%+44.64% 35TCr
+0.71%+4.08%+21.75%+28.83% 27TCr
+1.23%+0.42%+14.11%+12.43% 26TCr
+2.11%+7.51%+51.88%+54.11% 22TCr
+0.83%+0.55%+34.64%+99.83% 19TCr
0.00%-10.14%-27.40%-61.08% 17TCr
Average +0.57%-0.26%+21.19%+33.66% 36.39TCr
Weighted average by Cap. +0.27%+1.32%+40.42%+68.21%

Financials

2026 *2027 *
Net sales 5.5Cr 4.83Cr 4.56Cr 4.15Cr 7.78Cr 527.18Cr 7.83Cr 55Cr 21Cr 269.32Cr 21Cr 20Cr 865.58Cr 11Cr 9.73Cr 9.19Cr 8.37Cr 16Cr 1.06TCr 16Cr 109.97Cr 43Cr 542.97Cr 42Cr 41Cr 1.75TCr
Net income -17Cr -15Cr -14Cr -13Cr -24Cr -1.62TCr -24Cr -167.34Cr -65Cr -826.2Cr -63Cr -62Cr -2.66TCr -16Cr -14Cr -14Cr -12Cr -23Cr -1.57TCr -23Cr -162.94Cr -63Cr -804.49Cr -62Cr -60Cr -2.59TCr
Net Debt - -
Logo Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
142
Date Price Change Volume
25/26/25 $9.860 +1.65% 3,80,573
24/26/24 $9.700 -5.27% 6,14,799
23/26/23 $10.24 -3.31% 9,13,584
22/26/22 $10.59 -1.21% 5,86,134
21/26/21 $10.72 -1.38% 5,24,987
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
9.860USD
Average target price
44.50USD
Spread / Average Target
+351.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TNXP Stock